摘要
目的通过观察在炎症状态下他汀类药物对慢性肾脏病的降脂治疗效果,探讨脂代谢紊乱与炎症的关系及炎性反应导致细胞/机体对他汀类药物的可能抵抗机制。方法选取2013年1月-2014年12月泸州医学院肾脏内科收治住院的慢性肾炎伴高脂血症及原发病为慢性肾炎的肾衰竭患者、单纯性高脂血症患者各10例,均给予阿托伐他汀钙10mg口服1月,检测治疗前后血脂指标(TC、TG、LDL、HDL)及炎症指标(CRP)的变化情况。结果用药前肾衰竭组TC、TG、HDL、CRP与对照组相比,差异有统计学意义(P<0.05)。用药后慢性肾炎组TC、CRP及肾衰竭组TC、LDL、CRP与对照组相比,差异有统计学意义(P<0.05);慢性肾炎组及肾衰竭组各组内相比血脂各项均较用药前有所下降,HDL有所升高,其中对照组血脂各项,慢性肾炎组TC、LDL差异有统计学意义(P<0.05),肾衰竭组治疗后各项指标较用药前比较差异无统计学意义(P>0.05)。结论阿托伐他汀钙具有非依赖调脂的肾脏保护作用,随着肾小球滤过率(GFR)的逐渐减退少而炎症逐渐加重,调脂作用越小,炎症具有一定程度的抵抗作用。
Objective To observe inflammation in statin lipid-lowering treatment for chronic kidney disease,and to explore the relationship between lipid metabolism and inflammation and inflammation leading to possible resistance mechanisms of cell / body of the statin drugs. Methods Patients with renal failure in January 2013- 2014 chronic glomerulonephritis with hyperlipidemia and primary disease in December Luzhou Medical Nephrology admitted to hospital for chronic nephritis,simple hyperlipidemic patients 10 cases,were given 10 mg of atorvastatin calcium oral January,before and after treatment to detect serum lipids（ TC,TG,LDL,HDL） and inflammatory markers（ CRP） of the change; Results Renal failure before treatment group TC,TG,HDL,CRP Compared with the control group,the difference was statistically significant（ P〈0. 05）; after treatment of chronic nephritis group TC,CRP and kidney failure group TC,LDL,CRP compared with the control group,the difference was significant（ P〈0. 05）; chronic nephritis group and renal failure group compared with the drug compared to the previous lipids decreased in each group,HDL was increased,which controls blood lipids,chronic nephritis group TC,LDL were significantly different（ P〈0. 05）; renal failure group than before treatment were not statistically significant（ P〈0. 05）. Conclusion That atorvastatin calcium has the effect of anti-inflammatory and lipid; and prevalence of chronic kidney disease microinflammatory state,with the GFR gradually diminishes inflammation gradually increased,atorvastatin atorvastatin calcium Lipid Metabolism smaller.
出处
《临床合理用药杂志》
2016年第2期7-8,共2页
Chinese Journal of Clinical Rational Drug Use
关键词
炎症
脂代谢紊乱
慢性肾脏病
阿托伐他汀钙
Inflammation
Lipid metabolism
Chronic kidney disease
Atorvastatin
